An intergroup phase III trial of Ramucirumab plus Irinotecan in third or more line Beyond progression after Ramucirumab for Advanced Gastric cancer.

Trial Profile

An intergroup phase III trial of Ramucirumab plus Irinotecan in third or more line Beyond progression after Ramucirumab for Advanced Gastric cancer.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Ramucirumab (Primary) ; Irinotecan
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms RINDBeRG trial
  • Most Recent Events

    • 21 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 15 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top